MDM2 and rhabdomyosarcoma: Neither of the MDM2 inhibitors induced objective responses in osteosarcoma or neuroblastoma models, but in the limited number of models tested objective responses were noted for Ewing sarcoma (25 %), rhabdomyosarcoma (14 %), medulloblastoma (1 of 2), and other histologies.